Home › Compound Library › Vitamin K2 (MK-7)

Vitamin K2 (MK-7)

Vitaminoral · inferred

Directs calcium to bones and teeth rather than arteries. Often paired with Vitamin D3 for synergistic effects.

Projected serum levels — 100 mcg (≈ 0.10 mg), once daily

Vitamin K2 (MK-7)
Vitamin K2 (MK-7) modeled serum levels, 100 mcg (≈ 0.10 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 100 mcg (≈ 0.10 mg) once daily (oral).

Modeled steady state after ~1 days: peak ≈ 0.017 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Vitamin
Route modeled
Oral
Model confidence
inferred
Half-life
1.7 h
Common dose
100 mcg (≈ 0.10 mg)
Suggested maximum
300 mcg/day
Reference dose range
50–300 mcg (single dose)
Suggested cadence
once daily
Validated against
45 mg oral — Cmax 0.30 mg/L at 4 h

Documented interactions

  • danger
    Levothyroxine (Synthroid) + Vitamin K2 (MK-7) Protein binding

    Vitamin K2 (MK-7) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

  • danger
    Warfarin (Coumadin) + Vitamin K2 (MK-7) Depletion

    Vitamin K2 (menaquinone) supplementation directly antagonizes warfarin's mechanism of action. Warfarin inhibits VKORC1, the enzyme that recycles vitamin K — supplemental vitamin K provides additional…

  • warning
    Apigenin + Vitamin K2 (MK-7) Protein binding

    Apigenin may displace Vitamin K2 (MK-7) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aripiprazole (Abilify) + Vitamin K2 (MK-7) Protein binding

    Aripiprazole (Abilify) may displace Vitamin K2 (MK-7) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Armour Thyroid (Desiccated Thyroid Extract) + Vitamin K2 (MK-7) Protein binding

    Vitamin K2 (MK-7) may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Astaxanthin + Vitamin K2 (MK-7) Protein binding

    Astaxanthin may displace Vitamin K2 (MK-7) from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 140 modeled interaction pairings for vitamin k2 (mk-7) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. A high menaquinone intake reduces the incidence of coronary heart disease Geleijnse JM et al. · Nutrition, Metabolism and Cardiovascular Diseases, 2004 DOI

    Prospective cohort study found that high dietary vitamin K2 intake was associated with reduced coronary heart disease risk and aortic calcification.

  2. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women Knapen MH et al. · Osteoporosis International, 2013 DOI

    RCT showed that 180 mcg/day of MK-7 for 3 years significantly improved bone mineral content, bone strength, and reduced age-related bone loss in postmenopausal women.

  3. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study Geleijnse JM et al. · Journal of Nutrition, 2004 DOI

    Large population study (4807 subjects) found that adequate vitamin K2 intake was linked to 50% lower risk of arterial calcification and cardiovascular death.

  4. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C · Thrombosis and haemostasis, 2015 DOI

    This citation reports a human clinical study involving Vitamin K2 (MK-7). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

4 published studies referenced in the app, each with a plain-language summary.